Valion Bio: 1st National Registration Looms as Ukraine MOH Reviews Entolimod

Entolimod is Valion Bio's investigational medical countermeasure for acute radiation syndrome (ARS). The drug is intended to address the life-threatening consequences of high-dose radiation exposure, a concern that has become more salient in Ukraine because of the war and ongoing risks around nuclear facilities. Ukraine's Regulatory Equivalence Pathway suggests that the Ministry of Health may rely on certain foreign or prior regulatory data as part of its assessment, though Valion Bio has not specified which reference agencies or prior regulatory decisions underpin the application. The move into technical assessment is significant because it signals that the dossier was sufficiently complete to proceed past formal acceptance and into detailed, science-based review. The first round of questions on physicochemical characterization touches on drug substance and drug product consistency, an area of particular importance when a government might stockpile the medicine for emergency use.

The potential market impact for Valion Bio is meaningful but still uncertain. A favorable regulatory decision, which the company believes could occur as early as the fourth quarter of 2026, would represent Entolimod's first national registration anywhere. That would validate the program and could establish a pathway toward possible inclusion in Ukraine's national strategic reserves and future government procurement. However, the company explicitly states that no procurement, purchase, or stockpiling agreement has been executed, and there can be no assurance regarding timing or outcome. For health policy and emergency preparedness stakeholders, the review process itself is an important signal: Ukraine is building domestic regulatory capacity for medical countermeasures at a time when radiological and nuclear threats are part of the national security conversation. The outcome will depend on how cleanly Valion Bio addresses the Ministry's technical questions, whether additional rounds of questions arise, and whether the regulatory pathway translates into an actual procurement commitment or remains a registration-only milestone.